奥马环素治疗耐多药粪肠球菌腹膜炎模型小鼠的疗效。
Efficacy of Omadacycline against Multidrug-Resistant Enterococcus faecium Strains in a Mouse Peritonitis Model.
机构信息
Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
UTHealth Center for Antimicrobial Resistance and Microbial Genomics (CARMiG), Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0070921. doi: 10.1128/AAC.00709-21.
Abstract
Omadacycline (OMC) showed better potency than daptomycin (DAP) or vancomycin (VAN) against Van, Amp, DAP-nonsusceptible, linezolid-resistant, (B) Enterococcus faecium strains. In a mouse peritonitis model, OMC also showed significantly better animal survival during the study and at its end than DAP or VAN with these E. faecium strains. However, OMC, DAP, and VAN showed comparable and efficacies against a non-vancomycin-resistant, tetracycline-resistant, DAP-susceptible E. faecium strain.
摘要
奥马环素（OMC）对耐万古霉素、耐氨苄西林、DAP 中介、利奈唑烷耐药（B）粪肠球菌的活性优于达托霉素（DAP）或万古霉素（VAN）。在一项小鼠腹膜炎模型研究中，与 DAP 或 VAN 相比，OMC 也显著提高了这些粪肠球菌菌株感染的动物存活率。然而，OMC、DAP 和 VAN 对非万古霉素耐药、四环素耐药、DAP 敏感的粪肠球菌的疗效相当。
相似文献
1
Efficacy of Omadacycline against Multidrug-Resistant Enterococcus faecium Strains in a Mouse Peritonitis Model.
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0070921. doi: 10.1128/AAC.00709-21.
2
Efficacy of Tedizolid against Enterococci and Staphylococci, Including Strains, in a Mouse Peritonitis Model.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02627-18. Print 2019 Apr.
3
Comparative efficacies of daptomycin, vancomycin, and linezolid in experimental enterococcal peritonitis.
J Infect Chemother. 2017 Jul;23(7):498-501. doi: 10.1016/j.jiac.2016.12.002. Epub 2017 Jan 17.
4
Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium.
J Infect Dis. 2020 Oct 1;222(9):1531-1539. doi: 10.1093/infdis/jiaa319.
5
Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
Int J Antimicrob Agents. 2021 Jul;58(1):106353. doi: 10.1016/j.ijantimicag.2021.106353. Epub 2021 May 5.
6
Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00315-18. Print 2018 Aug.
7
Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy.
Antimicrob Agents Chemother. 2013 Jan;57(1):261-8. doi: 10.1128/AAC.01454-12. Epub 2012 Oct 31.
8
β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
Antimicrob Agents Chemother. 2015 May;59(5):2842-8. doi: 10.1128/AAC.00053-15. Epub 2015 Mar 9.
9
LiaX is a surrogate marker for cell envelope stress and daptomycin non-susceptibility in .
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0106923. doi: 10.1128/aac.01069-23. Epub 2024 Jan 30.
10
Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.
Antimicrob Agents Chemother. 2003 Nov;47(11):3561-6. doi: 10.1128/AAC.47.11.3561-3566.2003.
引用本文的文献
1
Omadacycline for Diverse Infections in China: A Real-World Analysis of Efficacy and Safety.
Infect Dis Ther. 2024 Dec;13(12):2509-2526. doi: 10.1007/s40121-024-01065-3. Epub 2024 Oct 22.
本文引用的文献
1
Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Drugs. 2020 Feb;80(3):285-313. doi: 10.1007/s40265-020-01257-4.
2
Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model.
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.02058-19.
3
Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline.
Clin Infect Dis. 2019 Aug 1;69(Suppl 1):S16-S22. doi: 10.1093/cid/ciz309.
4
Microbiology and Preclinical Review of Omadacycline.
Clin Infect Dis. 2019 Aug 1;69(Suppl 1):S6-S15. doi: 10.1093/cid/ciz395.
5
Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00624-19. Print 2019 Jul.
6
Disrupting Membrane Adaptation Restores In Vivo Efficacy of Antibiotics Against Multidrug-Resistant Enterococci and Potentiates Killing by Human Neutrophils.
J Infect Dis. 2019 Jul 2;220(3):494-504. doi: 10.1093/infdis/jiz131.
7
Omadacycline: A Novel Tetracycline Derivative With Oral and Intravenous Formulations.
Clin Infect Dis. 2019 Aug 16;69(5):890-896. doi: 10.1093/cid/ciz242.
8
Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
J Glob Antimicrob Resist. 2019 Dec;19:56-63. doi: 10.1016/j.jgar.2019.02.017. Epub 2019 Feb 27.
9
Efficacy of Tedizolid against Enterococci and Staphylococci, Including Strains, in a Mouse Peritonitis Model.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02627-18. Print 2019 Apr.
10
Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02368-16. Print 2017 May.
Zotero 插件